596 related articles for article (PubMed ID: 25652749)
1. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH
J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile.
Corbett D; Wise A; Birchall S; Warn P; Baines SD; Crowther G; Freeman J; Chilton CH; Vernon J; Wilcox MH; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1751-6. PubMed ID: 25652750
[TBL] [Abstract][Full Text] [Related]
4. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.
Vickers R; Robinson N; Best E; Echols R; Tillotson G; Wilcox M
BMC Infect Dis; 2015 Feb; 15():91. PubMed ID: 25880933
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.
Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH
J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182
[TBL] [Abstract][Full Text] [Related]
6. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.
Freeman J; Vernon J; Vickers R; Wilcox MH
Antimicrob Agents Chemother; 2016 Jan; 60(1):689-92. PubMed ID: 26552981
[TBL] [Abstract][Full Text] [Related]
8. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
[TBL] [Abstract][Full Text] [Related]
9. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986
[TBL] [Abstract][Full Text] [Related]
10. In vivo assessment of SMT19969 in a hamster model of clostridium difficile infection.
Weiss W; Pulse M; Vickers R
Antimicrob Agents Chemother; 2014 Oct; 58(10):5714-8. PubMed ID: 25022586
[TBL] [Abstract][Full Text] [Related]
11. Fidaxomicin for the treatment of Clostridium difficile infections.
Whitman CB; Czosnowski QA
Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
[TBL] [Abstract][Full Text] [Related]
12. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
13. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin--the new drug for Clostridium difficile infection.
Vaishnavi C
Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
16. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
17. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
Venugopal AA; Johnson S
Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854
[TBL] [Abstract][Full Text] [Related]
18. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
Miller M
Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
[TBL] [Abstract][Full Text] [Related]
19. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
[No Abstract] [Full Text] [Related]
20. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
